Incyte Corp
NASDAQ:INCY
Incyte Corp
NASDAQ:INCY
Price:
57.18 USD
0.56%
Market Closed
Updated:
May 17, 2024
Incyte Corp
Operating Expenses
|
Incyte Corp
Operating Expenses Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Incyte Corp
NASDAQ:INCY
|
Operating Expenses
-$2.8B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-21%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$19.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$12.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$12.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$4.8B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$7.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-19%
|
See Also
What is Incyte Corp's Operating Expenses?
Operating Expenses
-2.8B
USD
-2.8B
USD
Based on the financial report for Mar 31, 2024, Incyte Corp's Operating Expenses amounts to -2.8B USD.
What is Incyte Corp's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-21%
-21%
Over the last year, the Operating Expenses growth was -2%. The average annual Operating Expenses growth rates for Incyte Corp have been -12% over the past three years , -12% over the past five years , and -21% over the past ten years .
You don't have any saved screeners yet
